24 October 2023: Aker BioMarine ASA today announces that it has acquired all krill related patents, pre-clinical and clinical data, and processing equipment from Nasdaq listed Acasti Pharma Inc. The transaction is a settlement towards a contractual obligation of USD 3.1 million Acasti has towards Aker BioMarine, and has no cash effects.
With this transaction Aker BioMarine continues to consolidate all relevant krill intellectual properties (IP), and further strengthen its leadership position.
The data acquired, which documents the strong cardiovascular benefits from krill oil, will further strengthen the attractiveness of Superba® krill oil in the dietary supplement market. In addition, this gives Aker BioMarine an option to later pursue pharmaceutical opportunities originated from Acasti Pharma Inc. The company currently has no plans of pursuing that option.
For further information, please contact
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.